This isn't a particularly healthy environment for smaller med-techs, and Wright Medical Group (NASDAQ:WMGI)
is paying the price for that sector weakness. There wasn't anything
particularly wrong with Wright Medical's second quarter report, and the
company continues to perform exceptionally well in the fast-growing
extremities market, but there was nothing new to push analysts or
investors to a more positive outlook. With market share growth potential
in lower extremities, an upcoming FDA decision on Augment, and the
balance sheet flexibility to do deals, there are still good reasons to
hold Wright Medical, but the discount to fair value doesn't scream "must
buy" right now.
Please continue here:
Wright Medical, Wrong Market
No comments:
Post a Comment